40
Participants
Start Date
June 10, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2030
PHP
Patients will be treated with 2 cycles of PHP (CHEMOSAT® Hepatic Delivery System for Melphalan) six weeks apart
IPI1/NIVO3
Patients will be treated with 2 cycles of i.v. ipilimumab 1mg/kg and nivolumab 3mg/kg q3w, followed by continued i.v. nivolumab 480mg q4w up to 1 year.
IPI3/NIVO1
Patients will be treated with 4 cycles of intravenous (i.v.) infusion with ipilimumab 3mg/kg and nivolumab 1mg/kg q3w followed by continued i.v. nivolumab 480mg q4w up to 1 year.
RECRUITING
Sahlgrenska University Hospital, Gothenburg
NOT_YET_RECRUITING
Linköping University Hospital, Linköping
NOT_YET_RECRUITING
Skåne University Hospital, Lund
RECRUITING
Karolinska University Hospital,, Stockholm
NOT_YET_RECRUITING
Norrland University Hospital, Umeå
RECRUITING
Uppsala University Hospital, Uppsala
Vastra Gotaland Region
OTHER_GOV